20 results on '"Magrey, M."'
Search Results
2. POS0805 SUSTAINED IMPROVEMENTS WITH BIMEKIZUMAB IN PATIENT-REPORTED SYMPTOMS OF AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
3. POS0806 LONG-TERM SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
4. AB1042 LUPUS NEPHRITIS IN LATE VERSUS EARLY ONSET SYSTEMIC LUPUS ERYTHEMATOSUS: A SYSTEMATIC REVIEW AND META-ANALYSIS
5. AB0909 SEX- RELATED DIFFERENCES IN EFFICACY OF BIOLOGICS IN AXIAL SPONDYLOARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
6. POS1143 TOTAL COST RISK SCORES AND BARRIER CATEGORIES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND ASSOCIATED FACTORS
7. POS0735 CHANGES IN PROPORTIONATE MORTALITY PATTERN IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN THE UNITED STATES FROM 1999 TO 2020
8. POS1541 LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: 3-YEAR RESULTS FROM THE PHASE 3 SELECT-PsA 1 STUDY
9. AB0947 EFFECT OF UPADACITINIB ON REDUCING PAIN IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS AND INADEQUATE RESPONSE TO BIOLOGIC THERAPY
10. AB0198 THRESHOLDS OF PRESENTEEISM MEASUREMENT INSTRUMENTS FOR UNACCEPTABLE WORK PARTICIPATION AND FUTURE ADVERSE WORK OUTCOMES IN RA
11. POS1107 BIMEKIZUMAB ACHIEVED SUSTAINED IMPROVEMENTS IN EFFICACY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, REGARDLESS OF PRIOR TNF INHIBITOR TREATMENT: WEEK 52 POOLED RESULTS FROM TWO PHASE 3 STUDIES
12. AB1000 ACHIEVEMENT OF INCREASINGLY STRINGENT CLINICAL RESPONSE CRITERIA AND LOWER LEVELS OF DISEASE ACTIVITY WAS ASSOCIATED WITH GREATER IMPROVEMENTS IN PHYSICAL FUNCTION AND HRQOL IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM TWO PHASE 3 STUDIES ON BIMEKIZUMAB
13. AB0937 TOFACITINIB EFFICACY AND SAFETY IN PATIENTS WITH ANKYLOSING SPONDYLITIS BY BASELINE C‑REACTIVE PROTEIN LEVELS: A POST HOC ANALYSIS
14. POS1106 ACHIEVEMENT OF LOW DISEASE ACTIVITY OVER 52 WEEKS IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS ON BIMEKIZUMAB TREATMENT: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2
15. POS0664 DEFINING THRESHOLDS OF PRESENTEEISM MEASURES FOR UNACCEPTABLE WORK PARTICIPATION IN AxSpA
16. POS1103 BIMEKIZUMAB MAINTAINED IMPROVEMENTS IN EFFICACY ENDPOINTS AND HAD A CONSISTENT SAFETY PROFILE THROUGH 52 WEEKS IN PATIENTS WITH NON-RADIOGRAPHIC AND RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PARALLEL PHASE 3 STUDIES
17. SAT0263 Predictors of remission maintenance and successful therapy discontinuation in patients with non-radiographic axial spondyloarthritis (NR-AXSPA) who achieved sustained remission on open-label adalimumab (ADA) treatment
18. OP0026 Adalimumab serum concentration fails to predict achievement of sustained remission or absence of flare for patients with non-radiographic axial spondyloarthritis in the ability-3 study
19. SAT0300 Treatment experience and satisfaction in ankylosing spondylitis patients treated with secukinumab: results from a us web-based survey
20. OP0243 Predictors of remission at week 12 in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab treatment in the ability-3 study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.